IP Library Granted Patent US 9,873,901
Granted Patent B2
US 9,873,901 · App. 14/498,827 · Granted Jan 23, 2018

Compositions and methods for reverse transcriptase-polymerase chain reaction (RT-PCR)

Inventors: Jun Lee (San Diego, CA); Ayoub Rashtchian (Gaithersburg, MD)
Assignee: LIFE TECHNOLOGIES CORPORATION
C12P19/34C12N9/1276C12N15/1096C12Q1/6846
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,873,901
App. No.
14/498,827
Granted
Jan 23, 2018
Kind
B2
Abstract

The present invention is directed to compositions and methods useful for the amplification of nucleic acid molecules by reverse transcriptase-polymerase chain reaction (RT-PCR). Specifically, the invention provides compositions and methods for the amplification of nucleic acid molecules in a simplified one- or two-step RT-PCR procedure using combinations of reverse transcriptase and thermostable DNA polymerase enzymes in conjunction with sulfur-containing molecules or acetate-containing molecules (or combinations of such sulfur-containing molecules and acetate-containing molecules), and optionally bovine serum albumin. The invention thus facilitates the rapid and efficient amplification of nucleic acid molecules and the detection and quantitation of RNA molecules. The invention also is useful in the rapid production and amplification of cDNAs which may be used for a variety of industrial, medical and forensic purposes.

Claims (18)

1. A composition suitable for carrying out a one-step reverse transcriptase-polymerase chain reaction (RT-PCR) comprising a Moloney murine leukemic virus (M-MLV) reverse transcriptase (RT), one or more DNA polymerases, a non-naturally occurring buffering agent, and bovine serum albumin, wherein said one or more DNA polymerases is selected from the group consisting of Tne, Tma, Taq, Pfu, Tth, Tfi, Pwo, and Tfl; or wherein said one or more DNA polymerases comprises a first DNA polymerase having 3′ exonuclease activity and a second DNA polymerase having substantially reduced 3′ exonuclease activity; and wherein the unit ratio of said RT to said DNA polymerase(s) is greater than about 3:2; and wherein said bovine serum albumin is at a concentration of about 2 to 20 μg/ml.

2. The composition of claim 1 , wherein said bovine serum albumin is at a concentration which relieves RT inhibition of nucleic acid amplification.

3. The composition of claim 1 , further comprising one or more sulfur-containing molecules, one or more acetate-containing molecules, and/or one or more potassium-containing molecules.

4. The composition of claim 3 , wherein said one or more acetate-containing molecules is at a concentration of about 1 mM to about 500 mM.

5. The composition of claim 3 , wherein said one or more sulfur-containing molecules is at a concentration of at least 18 mM sulphur.

6. The composition of claim 1 , wherein

(a) said DNA polymerase having 3′ exonuclease activity is selected from the group consisting of Pfu, Pwo, Tne, Tma, Kod, and mutants, variants and derivatives thereof; and/or

(b) said DNA polymerase having substantially reduced 3′ exonuclease activity is selected from the group consisting of Taq, Tfl, Tth, and mutants, variants and derivatives thereof.

7. The composition of claim 3 , wherein a source of said one or more sulfur-containing molecules is selected from:

(a) a sulfur-containing buffer; or

(b) a sulfur-containing salt.

8. The composition of claim 3 , wherein a source of said one or more acetate-containing molecules is selected from:

(a) an acetate-containing salt; or

(b) an acetate-containing buffer.

9. The composition of claim 1 , further comprising one or more nucleotides which are deoxyribonucleoside triphosphates or derivatives thereof, or dideoxyribonucleoside triphosphates or derivatives thereof.

10. The composition of claim 1 , wherein said reverse transcriptase is substantially reduced in RNase H activity.

11. The composition of claim 1 , wherein said reverse transcriptase is a mutant Moloney murine leukemic virus (M-MLV) reverse transcriptase.

12. The composition of claim 1 , further comprising one or more oligonucleotide primers.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2016
From: LEE, JUN; RASHTCHIAN, AYOUB
To: LIFE TECHNOLOGIES, INC.
Reel/Frame 039634/0831 →
MERGER Recorded Sep 6, 2016
From: LIFE TECHNOLOGIES, INC.
To: INVITROGEN CORPORATION
Reel/Frame 039635/0294 →
MERGER Recorded Sep 6, 2016
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 039635/0356 →
Continuity (8)
Continuation 13764754 · Feb 11, 2013
Continuation 12981240 · Dec 29, 2010
Continuation 10861469 · Jun 7, 2004
Continuation 10224334 · Aug 21, 2002
Continuation 09472066 · Dec 23, 1999
Continuation 09054485 · Apr 3, 1998
Provisional Application 60042629 · Apr 3, 1997
Related Publication 20150017688A1 · Jan 15, 2015